Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,399 result(s) found. Displaying page 2,175 of 2,220.
    «« First « Previous 2171  2172  2173  2174  2175  2176  2177  2178  2179  Next» Last»»
    EudraCT Number: 2021-005738-41 Sponsor Protocol Number: CXXB750B12201 Start Date*: 2022-11-25
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10081349 Resistant hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) CZ (Completed) SK (Completed) IT (Completed) NL (Completed) DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003969-33 Sponsor Protocol Number: IPH4102-201 Start Date*: 2019-03-05
    Sponsor Name:Innate Pharma SA
    Full Title: TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in p...
    Medical condition: Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) and Peripheral T Cell Lympomas (PTCL). CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    20.0 100000004851 10002450 Angioimmunoblastic T-cell lymphomas HLT
    20.0 100000004851 10002235 Anaplastic large cell lymphomas T- and-cell types HLT
    20.0 100000004851 10028484 Mycoses fungoides HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Temporarily Halted) IT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006540-28 Sponsor Protocol Number: LEVI-04-21-02 Start Date*: 2022-07-21
    Sponsor Name:Levicept Ltd.
    Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients with Osteoarthritis of the Knee
    Medical condition: Osteoarthritis of the knee
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001193-34 Sponsor Protocol Number: STRIB-PEP Start Date*: 2014-07-16
    Sponsor Name:Fundació Clínic per a la recerca biomèdica
    Full Title: COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICIS...
    Medical condition: Prophilaxis VIH infecction post accidental exposition (PPE)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004538-40 Sponsor Protocol Number: BC-5429 Start Date*: 2020-11-20
    Sponsor Name:Ghent University Hospital
    Full Title: A multicentric randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children.
    Medical condition: Gram positive infection
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005971-11 Sponsor Protocol Number: AP101-02 Start Date*: 2021-10-20
    Sponsor Name:AL-S Pharma, AG
    Full Title: A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyot...
    Medical condition: Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002679-12 Sponsor Protocol Number: EOCRC1-22 Start Date*: 2023-06-01
    Sponsor Name:Enterome SA
    Full Title: A phase 2 trial of EO2040, a miCrobiaL-derived peptide therApeUtic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-dEfined minimal residual disease of c...
    Medical condition: Patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of curative therapy .
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010033 Colorectal cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001075-17 Sponsor Protocol Number: AdvanTIG-205 Start Date*: 2022-05-26
    Sponsor Name:BeiGene, Ltd.
    Full Title: AdvanTIG-205: A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitiz...
    Medical condition: Metastatic non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012978-12 Sponsor Protocol Number: ME026 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Serono, an affiliate of E. Merck AB
    Full Title: A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial to be conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® ...
    Medical condition: Hyperphenylalaninemia (HPA) in adults and children >=16 years of age with phenylketonuri (PKU) (classic or mild PKU, or mild hyperphenylalaninemia (HPA)).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034872 Phenylketonuria LLT
    9.1 10034873 Phenylketonuria (PKU) LLT
    9.1 10034872 Phenylketonuria PT
    9.1 10034871 Phenylalaninemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002094-55 Sponsor Protocol Number: 1861 Start Date*: 2019-09-09
    Sponsor Name:Universitair Ziekenhuis Brussel, Belgium
    Full Title: Safety and feasibility of S-Caine patch use in children under the age of three
    Medical condition: children under the age of three that are in possession of a central catheter and under permanent monitoring (healthy, or any condition)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001699-41 Sponsor Protocol Number: MEQ00074 Start Date*: 2025-08-14
    Sponsor Name:Sanofi Pasteur
    Full Title: A Phase III, open-label, single-center study to describe the immunogenicity and safety of a single dose of MenACYW Conjugate Vaccine in participants aged 12 months and older in Vietnam
    Medical condition: Meningococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027274 Meningococcal infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002190-21 Sponsor Protocol Number: MAR-BAS-18-005 Start Date*: 2020-07-08
    Sponsor Name:Fondazione per la Medicina Personalizzata
    Full Title: The ROME trial from histology to target: the road to personalize target therapy and immunotherapy
    Medical condition: Patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066275 Comedocarcinoma of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007351 Carcinoma gastrointestinal LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071533 Lung squamous cell carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004653-69 Sponsor Protocol Number: BHV4157-303 Start Date*: 2021-09-27
    Sponsor Name:Biohaven Pharmaceuticals, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
    Medical condition: Obsessive Compulsive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10002860 Anxiety disorder NEC LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006426-43 Sponsor Protocol Number: IPAX-Linz-01 Start Date*: 2022-02-16
    Sponsor Name:Kepler Universitätsklinikum Linz Neuromed Campus
    Full Title: An open label, single arm monocentric phase II study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 4-L- [131I]iodophenylalanine (131I-IPA), administered as sequential ...
    Medical condition: Previously confirmed histological diagnosis of malignant brain tumours (glioma), with current clinical or imaging evidence for first or second recurrence
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004987-80 Sponsor Protocol Number: 2013-Colistin Start Date*: 2014-08-28
    Sponsor Name:CUB - Hôpital Erasme
    Full Title: Colistin use in Cystic Fibrosis patients: pharmacokinetic studies (intravenous administration) in relation with pharmacodynamics, tolerance profile and risk of selection of resistance.
    Medical condition: Colistin use in Cystic Fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005077-29 Sponsor Protocol Number: D4200C00058 Start Date*: 2006-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA ) versus Placebo in Subjects with Unresectable Locally Adva...
    Medical condition: Medullary thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) BE (Completed) HU (Completed) PT (Completed) SE (Completed) DK (Completed) AT (Completed) IT (Completed) GB (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-005602-10 Sponsor Protocol Number: 1.1 Start Date*: 2022-01-20
    Sponsor Name:Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB)
    Full Title: POESIA Study: Pleiotropic effects of PCSK 9 inhibition and bempedoic acid - Changes in Platelet Function and Inflammation Markers
    Medical condition: platelet activity and inflammation markers in patients with coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001043-41 Sponsor Protocol Number: 516-005 Start Date*: 2020-11-03
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Plat...
    Medical condition: Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) HU (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004441-33 Sponsor Protocol Number: MK-7902-013(E7080-G000-231) Start Date*: 2020-07-10
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
    Medical condition: Relapsed/Refractory pediatric solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) SE (Completed) HU (Completed) Outside EU/EEA BE (Completed) IT (Trial now transitioned) ES (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2015-005276-14 Sponsor Protocol Number: RGCH004 Start Date*: 2016-06-03
    Sponsor Name:Sykehuset Østfold HF
    Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2171  2172  2173  2174  2175  2176  2177  2178  2179  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 12 04:28:39 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA